Thomas Jefferson University

Veda Giri

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-503-5253
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R03CA150079     (GIRI, VEDA N.)Mar 1, 2010 - Feb 28, 2013
    NIH
    Clinical Utility of Genetic Markers Associated with Early Onset Prostate Cancer
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Jan 09; JCO2402608. PMID: 39787437.
      Citations:    
    2. Leader AE, Rebbeck TR, Oh WK, Patel AV, Winer EP, Bailey LO, Gomella LG, Lumpkins CY, Garraway IP, Aiello LB, Baskin ML, Cheng HH, Cooney KA, Ganzak A, George DJ, Halabi S, Hathaway F, Healy C, Kim JW, Leapman MS, Loeb S, Maxwell KN, McNair C, Morgan TM, Prindeville B, Soule HR, Steward WL, Suttiratana SC, Taplin ME, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri VN. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. BMC Public Health. 2024 Sep 18; 24(1):2533. PMID: 39289635.
      Citations:    
    3. Cheng HH, Shevach JW, Castro E, Couch FJ, Domchek SM, Eeles RA, Giri VN, Hall MJ, King MC, Lin DW, Loeb S, Morgan TM, Offit K, Pritchard CC, Schaeffer EM, Szymaniak BM, Vassy JL, Katona BW, Maxwell KN. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review. JAMA Oncol. 2024 Jul 25. PMID: 39052257.
      Citations:    
    4. Charnysh E, Pal S, Reader JM, Uhlmann WR, McCain S, Sanghavi K, Blasco D, Brandt R, Feero WG, Ferber R, Giri VN, Hendy K, Prince AER, Lee C, Roberts JS. Health care utilization and behavior changes after workplace genetic testing at a large US health care system. Genet Med. 2024 May 08; 26(8):101160. PMID: 38733246.
      Citations:    
    5. Loeb S, Keith SW, Cheng HH, Leader AE, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown LH, Pieczonka CM, Gomella LG, Kelly WK, Lallas CD, Handley N, Mille PJ, Mark JR, Brown GA, Chopra S, McClellan A, Wise DR, Hollifield L, Giri VN. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precis Oncol. 2024 Mar; 8:e2300552. PMID: 38452310.
      Citations:    
    6. Vandekerkhove G, Giri VN, Halabi S, McNair C, Hamade K, Bitting RL, Wyatt AW. Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. JCO Precis Oncol. 2024 Mar; 8:e2300654. PMID: 38547422.
      Citations:    
    7. Loeb S, Cheng HH, Paller CJ, Weg E, Johnson J, Gross L, Keith SW, Russo J, Hathaway F, Rivera A, Giri VN. Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. Prostate Cancer Prostatic Dis. 2024 Jan 03. PMID: 38172199.
      Citations:    
    8. Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, Giri VN, Miller J, Maley W, Shah AP, DiMeglio M, Ambelil M, Yu R, Sato T, Lefler DS. Liver Transplantation in a Woman with Mahvash Disease. N Engl J Med. 2023 Nov 23; 389(21):1972-1978. PMID: 37991855.
      Citations:    
    9. Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, Arun B, Buys SS, Cheng H, Domchek SM, Friedman S, Giri V, Goggins M, Hagemann A, Hendrix A, Hutton ML, Karlan BY, Kassem N, Khan S, Khoury K, Kurian AW, Laronga C, Mak JS, Mansour J, McDonnell K, Menendez CS, Merajver SD, Norquist BS, Offit K, Rash D, Reiser G, Senter-Jamieson L, Shannon KM, Visvanathan K, Welborn J, Wick MJ, Wood M, Yurgelun MB, Dwyer MA, Darlow SD. NCCN Guidelines? Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. J Natl Compr Canc Netw. 2023 Oct; 21(10):1000-1010. PMID: 37856201.
      Citations:    
    10. Ritch EJ, Herberts C, Warner EW, Ng SWS, Kwan EM, Bacon JVW, Bernales CQ, Sch?nlau E, Fonseca NM, Giri VN, Maurice-Dror C, Vandekerkhove G, Jones SJM, Chi KN, Wyatt AW. A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. NPJ Precis Oncol. 2023 Mar 13; 7(1):27. PMID: 36914848.
      Citations:    
    11. Loeb S, Sanchez Nolasco T, Siu K, Byrne N, Giri VN. Usefulness of podcasts to provide public education on prostate cancer genetics. Prostate Cancer Prostatic Dis. 2023 Jan 21. PMID: 36681741.
      Citations:    
    12. Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA, Morgan TM. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. Eur Urol. 2023 Jan 04. PMID: 36609003.
      Citations:    
    13. Giri VN, Oliver TK, Rumble RB, Friedberg JW, Miller KD, Geisel RL. ASCO Living Guidelines: The Next Frontier. J Clin Oncol. 2022 Dec 19; JCO2202344. PMID: 36534929.
      Citations:    
    14. Giri VN, Oliver TK, Rumble RB, Geisel RL. Reply to X. Luo et al. J Clin Oncol. 2022 Oct 31; JCO2202126. PMID: 36315930.
      Citations:    
    15. Thakker S, Loeb S, Giri VN, Bjurlin MA, Matulewicz RS. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urol Pract. 2023 Jan; 10(1):26-32. PMID: 37103438.
      Citations:    
    16. Leader AE, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri VN. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. J Community Genet. 2022 Jul 22. PMID: 35869324.
      Citations:    
    17. Gomella PT, Mark JR, Giri VN, Kelly WK, Gomella LG. Guidelines on Germline Testing for Urologic Tumor Syndromes. Eur Urol Focus. 2022 Jul 05. PMID: 35803854.
      Citations:    
    18. Loeb S, Cheng HH, Leader A, Gross L, Nolasco TS, Byrne N, Wise DR, Hollifield L, Brown LH, Slater E, Pieczonka C, Gomella LG, Kelly WK, Trabulsi EJ, Handley N, Lallas CD, Chandrasekar T, Mille P, Mann M, Mark JR, Brown G, Chopra S, Wasserman J, Phillips J, Somers P, Giri VN. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemp Clin Trials. 2022 Jun 13; 106821. PMID: 35710085.
      Citations:    
    19. Giri VN, Hartman R, Pritzlaff M, Horton C, Keith SW. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. JCO Precis Oncol. 2022 May; 6:e2200234. PMID: 35666082.
      Citations:    
    20. Russo J, Giri VN. Germline testing and genetic counselling in prostate cancer. Nat Rev Urol. 2022 Apr 21. PMID: 35449224.
      Citations:    
    21. Giri VN, Morgan TM, Morris DS, Berchuck JE, Hyatt C, Taplin ME. Genetic testing in prostate cancer management: Considerations informing primary care. CA Cancer J Clin. 2022 Feb 24. PMID: 35201622.
      Citations:    
    22. Giri VN. When to use germline genetic testing in prostate cancer. Clin Adv Hematol Oncol. 2022 02; 20(2):78-81. PMID: 35120087.
      Citations:    
    23. Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, Gomella LG, Fischer C, Loeb S. Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. Clin Genitourin Cancer. 2021 Nov 27. PMID: 35012874.
      Citations:    
    24. Giri VN, Shimada A, Leader AE. Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine. JCO Precis Oncol. 2021; 5. PMID: 34778693.
      Citations:    
    25. Martin NA, Tepper JE, Giri VN, Stinchcombe TE, Cheng HH, Javle MM, Konnick EQ. Adopting Consensus Terms for Testing in Precision Medicine. JCO Precis Oncol. 2021; 5. PMID: 34651094.
      Citations:    
    26. Loeb S, Massey P, Leader AE, Thakker S, Falge E, Taneja S, Byrne N, Rose M, Joy M, Walter D, Katz MS, Wong RL, Selvan P, Keith SW, Giri VN. Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis. JMIR Cancer. 2021 Sep 20; 7(3):e27063. PMID: 34542414.
      Citations:    
    27. Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann M, Mark JR, Mille PJ, Preate D, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN. Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. JCO Precis Oncol. 2021; 5. PMID: 34589662.
      Citations:    
    28. Gomella LG, Giri VN. Prostate Cancer Genetics: Changing the Paradigm of Care. Urol Clin North Am. 2021 Aug; 48(3):xiii-xiv. PMID: 34210497.
      Citations:    
    29. Mark JR, McDougall C, Giri VN. Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. Urol Clin North Am. 2021 Aug; 48(3):311-322. PMID: 34210487.
      Citations:    
    30. Peters CJ, Turner CE, Chesnut GT, Giri VN, Gomella LG, Shriver CD, Dobi A. Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine. Can J Urol. 2021 06; 28(3):10659-10667. PMID: 34129457.
      Citations:    
    31. Loeb S, Li R, Sanchez Nolasco T, Byrne N, Cheng HH, Becker D, Leader AE, Giri VN. Barriers and facilitators of germline genetic evaluation for prostate cancer. Prostate. 2021 Aug; 81(11):754-764. PMID: 34057231.
      Citations:    
    32. Loeb S, Giri VN. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. Eur Urol Oncol. 2020 Dec 31. PMID: 33390340.
      Citations:    
    33. Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, Reichert Z, Rettig MB, Ryan CJ, Taplin ME, Vinson J, Whang YE, Morgans AK, Cheng HH, McKay RR. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncol Pract. 2020 Dec; 16(12):811-819. PMID: 32986533.
      Citations:    
    34. Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN. Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation?,??. Cancer Treat Res Commun. 2020; 25:100212. PMID: 33091732.
      Citations:    
    35. Bruneau M, Milliron BJ, Sinclair E, Obeid E, Gross L, Bealin L, Smaltz C, Butryn M, Giri VN. Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: a teachable moment for improved survivorship. Support Care Cancer. 2020 Sep 02. PMID: 32876733.
      Citations:    
    36. Lynch SM, Handorf E, Sorice KA, Blackman E, Bealin L, Giri VN, Obeid E, Ragin C, Daly M. The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer. PLoS One. 2020; 15(8):e0237332. PMID: 32790761.
      Citations:    
    37. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 Jun 09; JCO2000046. PMID: 32516092.
      Citations:    
    38. Greidinger A, Miller-Samuel S, Giri VN, Woo MS, Akumalla S, Zeigler-Johnson C, Keith SW, Silver DP. Neuroendocrine Tumors Are Enriched in Cowden Syndrome. JCO Precis Oncol. 2020; 4. PMID: 32923874.
      Citations:    
    39. Giri VN, Hyatt C, Leader A. Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice. J Urol. 2020 12; 204(6):1116-1118. PMID: 32926644.
      Citations:    
    40. Giri VN. Genetic education and practice considerations of non-genetic providers. Can J Urol. 2019 Oct; 26(5S2):44-45. PMID: 31629430.
      Citations:    
    41. Gomella LG, Knudsen KE, Giri VN. Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'. Can J Urol. 2019 Oct; 26(5S2):1-4. PMID: 31629412.
      Citations:    
    42. Giri VN, Selvan P, Mohanty S, Lum R, Serrao S, Leader AE. Exploring Asian Indian views about cancer and participation in cancer research: an evaluation of a culturally tailored educational intervention. J Community Genet. 2019 Sep 14. PMID: 31522341.
      Citations:    
    43. Sannai M, Doneddu V, Giri V, Seeholzer S, Nicolas E, Yip SC, Bassi MR, Mancuso P, Cortellino S, Cigliano A, Lurie R, Ding H, Chernoff J, Sobol RW, Yen TJ, Bagella L, Bellacosa A. Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1. DNA Repair (Amst). 2019 Aug 08; 82:102687. PMID: 31476572.
      Citations:    
    44. Chandrasekar T, Gross L, Gomella LG, Hegarty SE, Leong JY, Giri VN. Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men. Eur Urol Oncol. 2019 Jul 02. PMID: 31278035.
      Citations:    
    45. Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer. 2019 Aug; 17(4):275-282.e1. PMID: 31171481.
      Citations:    
    46. Giri VN, Hyatt C, Gomella LG. Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision Management. J Clin Oncol. 2019 Apr 12; JCO1802181. PMID: 30978156.
      Citations:    
    47. Milliron BJ, Bruneau M, Obeid E, Gross L, Bealin L, Smaltz C, Giri VN. Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention. Prostate. 2019 Mar 24. PMID: 30905089.
      Citations:    
    48. Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate. 2019 Mar; 79(4):333-339. PMID: 30450585.
      Citations:    
    49. Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, Stadler WM, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018; 2018. PMID: 30761386.
      Citations:    
    50. Giri VN, Obeid E, Hegarty SE, Gross L, Bealin L, Hyatt C, Fang CY, Leader A. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate. 2018 Apr 14. PMID: 29655297.
      Citations:    
    51. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 01; 36(4):414-424. PMID: 29236593.
      Citations:    
    52. Giri VN, Yurgelun MB, Robson ME. The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration. Ann Intern Med. 2017 Dec 19; 167(12):884-885. PMID: 29086794.
      Citations:    
    53. Leader AE, Mohanty S, Selvan P, Lum R, Giri VN. Exploring Asian Indian and Pakistani views about cancer and participation in cancer genetics research: toward the development of a community genetics intervention. J Community Genet. 2017 Jun 28. PMID: 28660599.
      Citations:    
    54. Giri VN, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty SE, Montgomery S, Forman A, Bingler R, Kelly WK, Dicker AP, Winheld S, Trabulsi EJ, Chen DYT, Lallas CD, Allen BA, Daly MB, Gomella LG. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precis Oncol. 2017 May; 1. PMID: 34164591.
      Citations:    
    55. Truong H, Hegarty SE, Gomella LG, Kelly WK, Trabulsi EJ, Lallas CD, Giri VN. Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts. J Genet Couns. 2017 Jun; 26(3):548-555. PMID: 28101821.
      Citations:    
    56. Roussi P, Miller SM, Giri VN, Obeid E, Wen KY, Tagai EK, Scarpato J, Gross L, Roy G. Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style. J Health Psychol. 2016 Oct 01; 1359105316671188. PMID: 28810355.
      Citations:    
    57. Giri VN, Beebe-Dimmer JL. Familial prostate cancer. Semin Oncol. 2016 Oct; 43(5):560-565. PMID: 27899188.
      Citations:    
    58. Myers RE, Leader AE, Censits JH, Trabulsi EJ, Keith SW, Petrich AM, Quinn AM, Den RB, Hurwitz MD, Lallas CD, Hegarty SE, Dicker AP, Zeigler-Johnson CM, Giri VN, Ayaz H, Gomella LG. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. J Cancer Educ. 2016 Jul 15. PMID: 27418065.
      Citations:    
    59. Pilie PG, Giri VN, Cooney KA. HOXB13 and other high penetrant genes for prostate cancer. Asian J Androl. 2016 Jul-Aug; 18(4):530-2. PMID: 27034017.
      Citations:    
    60. Giri VN, Gross L, Gomella LG, Hyatt C. How I Do It: Genetic counseling and genetic testing for inherited prostate cancer. Can J Urol. 2016 Apr; 23(2):8247-53. PMID: 27085833.
      Citations:    
    61. Fleisher L, Davis SN, Gross L, Bagden L, Zakrzewski D, González E, Kandadai V, Rusten C, Baskett J, Obeid E, Giri VN. Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project. J Cancer Educ. 2016 Mar; 31(1):191-7. PMID: 25971432.
      Citations:    
    62. Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Andrake MD, Handorf ED, Bodian DL, Vockley JG, Dunbrack RL, Ross EA, Egleston BL, Hall MJ, Golemis EA, Giri VN, Daly MB. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget. 2015 Nov 24; 6(37):39614-33. PMID: 26485759.
      Citations:    
    63. Liu JC, Parajuli S, Blackman E, Gibbs D, Ellis A, Hull A, Beck JR, Giri V, Iherjirka P, Khurana JS, Ragin CR. High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort. Head Neck. 2016 Apr; 38 Suppl 1:E867-72. PMID: 25962720; PMCID: PMC4643423.
      Citations:    
    64. Hall MJ, Ruth KJ, Chen DY, Gross LM, Giri VN. Interest in genomic SNP testing for prostate cancer risk: a pilot survey. Hered Cancer Clin Pract. 2015; 13(1):11. PMID: 25874018.
      Citations:    
    65. Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014 Sep; 12(9):1339-46. PMID: 25190699.
      Citations:    
    66. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep; 12(9):1211-9; quiz 1219. PMID: 25190691.
      Citations:    
    67. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014 Sep; 66(3):489-99. PMID: 24484606.
      Citations:    
    68. Handorf E, Crumpler N, Gross L, Giri VN. Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer. J Genet Couns. 2014 Jun; 23(3):371-6. PMID: 24310616.
      Citations:    
    69. Chang BL, Hughes L, Chen DY, Gross L, Ruth K, Giri VN. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer. BJU Int. 2014 May; 113(5b):E150-6. PMID: 23937305.
      Citations:    
    70. Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, Eeles R, Fernandez P, Giri VN, Gueye SM, Haiman CA, Henderson BE, Heyns CF, Hu JJ, Ingles SA, Isaacs W, Jalloh M, John EM, Kibel AS, Kidd LR, Layne P, Leach RJ, Neslund-Dudas C, Okobia MN, Ostrander EA, Park JY, Patrick AL, Phelan CM, Ragin C, Roberts RA, Rybicki BA, Stanford JL, Strom S, Thompson IM, Witte J, Xu J, Yeboah E, Hsing AW, Zeigler-Johnson CM. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer. 2013; 2013:560857. PMID: 23476788.
      Citations:    
    71. Hughes L, Zhu F, Ross E, Gross L, Uzzo RG, Chen DY, Viterbo R, Rebbeck TR, Giri VN. Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection. Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):53-60. PMID: 22144497.
      Citations:    
    72. Hall MJ, Ruth K, Giri VN. Rates and predictors of colorectal cancer screening by race among motivated men participating in a Prostate Cancer Risk Assessment Program. Cancer. 2012 Jan 15; 118(2):478-84. PMID: 21751189.
      Citations:    
    73. Smaldone MC, Giri VN, Uzzo RG. Familial clustering of sporadic kidney cancer: insufficient evidence to recommend routine screening in unaffected kin. Eur Urol. 2011 Nov; 60(5):994-5; discussion 995-7. PMID: 21741161.
      Citations:    
    74. Ishak MB, Giri VN. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1599-610. PMID: 21715604.
      Citations:    
    75. Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, Benford ML, Kidd LR, Cooney K, Strom S, Ingles SA, Stern MC, Corral R, Joshi AD, Xu J, Giri VN, Rybicki B, Neslund-Dudas C, Kibel AS, Thompson IM, Leach RJ, Ostrander EA, Stanford JL, Witte J, Casey G, Eeles R, Hsing AW, Chanock S, Hu JJ, John EM, Park J, Stefflova K, Zeigler-Johnson C, Rebbeck TR. Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev. 2011 Jan; 20(1):23-32. PMID: 21071540.
      Citations:    
    76. Giri VN, Ruth K, Hughes L, Uzzo RG, Chen DY, Boorjian SA, Viterbo R, Rebbeck TR. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU Int. 2011 Feb; 107(3):466-70. PMID: 20735386.
      Citations:    
    77. Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Stroup AM, Wake R, Wei JT. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010 Feb; 8(2):240-62. PMID: 20141680.
      Citations:    
    78. Tseng M, Giri V, Watkins-Bruner D, Giovannucci E. Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer. Cancer Causes Control. 2009 Dec; 20(10):1947-54. PMID: 19578936.
      Citations:    
    79. Giri VN, Coups EJ, Ruth K, Goplerud J, Raysor S, Kim TY, Bagden L, Mastalski K, Zakrzewski D, Leimkuhler S, Watkins-Bruner D. Prostate cancer early detection program recruitment methods and show rates in men at high risk. J Urol. 2009 Nov; 182(5):2212-7. PMID: 19758657.
      Citations:    
    80. Hughes L, Giri VN. Genetic polymorphisms and early-onset prostate cancer: a real potential to personalize prostate cancer screening? Future Oncol. 2009 Sep; 5(7):923-6. PMID: 19792959.
      Citations:    
    81. Kaplan DJ, Boorjian SA, Ruth K, Egleston BL, Chen DY, Viterbo R, Uzzo RG, Buyyounouski MK, Raysor S, Giri VN. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU Int. 2010 Feb; 105(3):334-7. PMID: 19709072.
      Citations:    
    82. Tseng M, Giri V, Bruner DW, Giovannucci E. Prevalence and correlates of vitamin D status in African American men. BMC Public Health. 2009 Jun 18; 9:191. PMID: 19534831.
      Citations:    
    83. Giri VN, Egleston B, Ruth K, Uzzo RG, Chen DY, Buyyounouski M, Raysor S, Hooker S, Torres JB, Ramike T, Mastalski K, Kim TY, Kittles R. Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila). 2009 Mar; 2(3):244-50. PMID: 19240249.
      Citations:    
    84. Mastalski K, Coups EJ, Ruth K, Raysor S, Giri VN. Substantial family history of prostate cancer in black men recruited for prostate cancer screening: results from the Prostate Cancer Risk Assessment Program. Cancer. 2008 Nov 1; 113(9):2559-64. PMID: 18816608.
      Citations:    
    85. Bryan CJ, Wetmore-Arkader L, Calvano T, Deatrick JA, Giri VN, Bruner DW. Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk. J Natl Med Assoc. 2008 Jun; 100(6):674-82. PMID: 18595569.
      Citations:    
    86. Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, Hanks G, Godwin AK, Chen DY, Gordon R, Cescon T, Raysor S, Watkins-Bruner D. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol. 2007 Nov; 178(5):1920-4; discussion 1924. PMID: 17868726.
      Citations:    
    87. Hwang C, Giri VN, Wilkinson JC, Wright CW, Wilkinson AS, Cooney KA, Duckett CS. EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. Breast Cancer Res Treat. 2008 Jan; 107(2):235-42. PMID: 17453341.
      Citations:    
    88. Hayward RA, Cowan C, Giri V, Lawrence MG, Makki F. Causes of preventable visual loss in type 2 diabetes mellitus: an evaluation of suboptimally timed retinal photocoagulation. J Gen Intern Med. 2005 May; 20(5):467-9. PMID: 15963174.
      Citations:    
    89. Giri VN, Cassidy AE, Beebe-Dimmer J, Ellis L, Smith DC, Bock CH, Cooney KA. Association between Agent Orange and prostate cancer: a pilot case-control study. Urology. 2004 Apr; 63(4):757-60; discussion 760-1. PMID: 15072895.
      Citations:    
    90. Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK, Jones M, Gildea D, Riedesel E, Albertus J, Freas-Lutz D, Markey C, Giri V, Dimmer JB, Montie JE, Trent JM, Cooney KA. Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate. 2003 Dec 1; 57(4):326-34. PMID: 14601029.
      Citations:    
    Giri's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (177)
    Explore
    _
    Co-Authors (43)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _